Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients

Wang,Jing; Zhang,Yuhai; Xu,Shudi; Li,Weijie; Chen,Zhangqin; Wang,Zhe; Han,Xinpeng; Zhao,Yiling; Li,Shengqing

doi:10.3892/ol.2015.2842

Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients

Authors:
- Jing Wang
- Yuhai Zhang
- Shudi Xu
- Weijie Li
- Zhangqin Chen
- Zhe Wang
- Xinpeng Han
- Yiling Zhao
- Shengqing Li
View Affiliations

Affiliations: Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China, Department of Medical Statistics, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China, Department of Respiratory Medicine, Shaanxi Provincial Second People's Hospital, Xi'an, Shaanxi, P.R. China, Department of Pathology, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China
Published online on: January 2, 2015 https://doi.org/10.3892/ol.2015.2842
Pages: 1266-1272

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to retrospectively assess the correlation between the expression levels of proteins involved in G2/M arrest signaling pathways in non‑small cell lung cancer (NSCLC) tissue, as determined by immunohistochemical (IHC) methods, and the overall survival of patients with advanced stage NSCLC. IHC analysis of advanced NSCLC specimens was used to determine the expression levels of proteins involved in G2/M arrest signaling pathways, including ataxia telangiectasia mutated (ATM) kinase, ataxia telangiectasia and Rad3‑related (ATR) kinase, checkpoint kinase (Chk) 1, Chk2, cell division cycle 25C (Cdc25C), total cyclin‑dependent kinase 1 (Cdk1) and active Cdk1 signaling pathways, the latter of which refers to dephospho‑Cdk1 (Tyr15) and phospho‑Cdk1 (Thr161). Patients were enrolled continuously and followed up for ≥2 years. Univariate analysis demonstrated that the protein expression levels of dephospho‑Cdk1 (P=0.015) and phospho‑Cdk1 (P=0.012) exhibited prognostic significance, while the expression of the other proteins was not significantly associated with patient survival (ATM, P=0.843; ATR, P=0.245; Chk1, P=0.341; Chk2, P=0.559; Cdc25C, P=0.649; total Cdk1, P=0.093). Furthermore, the patients with tumors exhibiting low expression levels of active Cdk1 survived significantly longer than those with tumors exhibiting high active Cdk1 expression levels (P<0.05). In addition, Cox regression analysis demonstrated that the expression of active Cdk1 [odds ratio (OR), 0.624; 95% confidence ratio (CI), 0.400‑0.973; P=0.038] and the pathological tumor‑node‑metastasis stage (OR, 0.515; 95% CI, 0.297‑0.894; P=0.018) were significant independent prognostic factors for NSCLC. Therefore, the results of the present study indicated that active Cdk1 protein is an independent prognostic factor for advanced NSCLC and may validate Cdk1 as a therapeutic target for advanced NSCLC patients.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Travis WD, Brambilla E and Riely GJ: New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 31:992–1001. 2013. View Article : Google Scholar : PubMed/NCBI
3	Dickhoff C, Hartemink KJ, van de Ven PM, et al: Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function. Lung Cancer. 85:218–223. 2014. View Article : Google Scholar : PubMed/NCBI
4	Somasundaram A, Socinski MA and Burns TF: Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opin Pharmacother. 15:2693–2708. 2014. View Article : Google Scholar : PubMed/NCBI Omolo B, Carson C, Chu H, Zhou Y, Simpson DA, Hesse JE, Paules RS, Nyhan KC, Ibrahim JG and Kaufmann WK: A prognostic signature of G(2) checkpoint function in melanoma cell lines. Cell Cycle. 12:1071–1082. 2013. View Article : Google Scholar : PubMed/NCBI
5	Smith J, Tho LM, Xu N and Gillespie DA: The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
6	Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, et al: ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle. 5:994–1000. 2006. View Article : Google Scholar : PubMed/NCBI
7	Gatei M, Sloper K, Sorensen C, Syljuäsen R, Falck J, Hobson K, et al: Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem. 278:14806–14811. 2003. View Article : Google Scholar : PubMed/NCBI
8	Huang M, Miao ZH, Zhu H, Cai YJ, Lu W and Ding J: Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther. 7:1440–1449. 2008. View Article : Google Scholar : PubMed/NCBI
9	Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H and Elledge SJ: Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science. 277:1497–1501. 1997. View Article : Google Scholar : PubMed/NCBI
10	Peter M, Le Peuch C, Labbé JC, Meyer AN, Donoghue DJ and Dorée M: Initial activation of cyclin-B1-cdc2 kinase requires phosphorylation of cyclin B1. EMBO Rep. 3:551–556. 2002. View Article : Google Scholar : PubMed/NCBI
11	Fesquet D, Labbé JC, Derancourt J, Capony JP, Galas S, Girard F, et al: The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J. 12:3111–3121. 1993.PubMed/NCBI
12	Poon RY, Chau MS, Yamashita K and Hunter T: The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res. 57:5168–5178. 1997.PubMed/NCBI
13	Edge SB, Byrd DR, Compton CC, et al: Lung. AJCC Cancer Staging Manual. Seventh Edition. Springer; New York, NY: pp. 299–324. 2010
14	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: Tumors of the lung. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: pp. 1–68. 2004
15	Fisher D: Control of DNA replication by cyclin-dependent kinases in development. Results Probl Cell Differ. 53:201–217. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, et al: ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 60:401–407. 2008. View Article : Google Scholar
17	Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, et al: Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol. 5:320–325. 2010. View Article : Google Scholar : PubMed/NCBI
18	Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J and Goldstraw P: International Staging Committee and Participating Institutions: The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 4:792–801. 2009. View Article : Google Scholar : PubMed/NCBI
19	Buccheri G and Ferrigno D: Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest. 117:1247–1255. 2000. View Article : Google Scholar : PubMed/NCBI
20	Wu M, Zhao J, Song SW, Zhuo M, Wang X, Bai H, et al: EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 67:343–347. 2010. View Article : Google Scholar
21	Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, et al: Worse disease-free survival in never-smokers with ALK+lung adenocarcinoma. J Thorac Oncol. 7:90–97. 2012. View Article : Google Scholar
22	Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, et al: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 95:998–1004. 2006. View Article : Google Scholar : PubMed/NCBI
23	Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
24	Choi CM, Yang SC, Jo HJ, Song SY, Jeon YJ, Jang TW, et al: Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. Ann Oncol. 23:2088–2093. 2012. View Article : Google Scholar : PubMed/NCBI
25	Grabauskiene S, Bergeron EJ, Chen G, Chang AC, Lin J, Thomas DG, et al: CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells. Lung Cancer. 82:477–484. 2013. View Article : Google Scholar : PubMed/NCBI
26	Wu W, Fan YH, Kemp BL, Walsh G and Mao L: Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 58:4082–4085. 1998.PubMed/NCBI
27	Abdulkader I, Sánchez L, Cameselle-Teijeiro J, Gude F, Chávez JE, López-López R, et al: Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study. Oncol Rep. 14:1527–1531. 2005.PubMed/NCBI
28	Lamberto I, Plano D, Moreno E, Font M, Palop JA, Sanmartín C and Encío I: Bisacylimidoselenocarbamates cause G2/M arrest associated with the modulation of CDK1 and Chk2 in human breast cancer MCF-7 cells. Curr Med Chem. 20:1609–1619. 2013. View Article : Google Scholar : PubMed/NCBI
29	Chow JP and Poon RY: The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene. 32:4778–4788. 2013. View Article : Google Scholar
30	Chang HY, Shih MH, Huang HC, Tsai SR, Juan HF and Lee SC: Middle infrared radiation induces G2/M cell cycle arrest in A549 lung cancer cells. PLoS One. 8:e541172013. View Article : Google Scholar : PubMed/NCBI
31	Xiao D, Zeng Y, Hahm ER, Kim YA, Ramalingam S and Singh SV: Diallyl trisulfide selectively causes Bax- and Bak-mediated apoptosis in human lung cancer cells. Environ Mol Mutagen. 50:201–212. 2009. View Article : Google Scholar :
32	Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, et al: Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA. 103:10660–10665. 2006. View Article : Google Scholar : PubMed/NCBI
33	Raghavan P, Tumati V, Yu L, Chan N, Tomimatsu N, Burma S, et al: AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. Int J Radiat Oncol Biol Phys. 84:e507–e514. 2012. View Article : Google Scholar : PubMed/NCBI